hypertension - renin inhibitor - all type of patients clinical trials results meta-analysis

<h1> <a href="TM7-106-renin inhibitor -hypertension" > <strong>hypertension</strong> - renin inhibitor </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t9499.htm"> Schmieder (vs HCTZ), 2009 </a> <br> </td> <td> aliskiren 300 mg<br>  <i>versus</i> <br> hydrochlorothiazide 25 mg </td> <td> patients with essential hypertension </td> <td> follow-up 20 weeks<br> n=567/557<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t9500.htm"> AVOID, 2008 </a> <br> NCT00097955 </td> <td> aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months<br>  <i>versus</i> <br> placebo </td> <td> patients with hypertension and type 2 diabetes with nephropathy </td> <td> follow-up 6 months<br> n=301/298<br> Parallel groups<br> double blind <br> 15 countries </td> </tr> <tr> <td> <a href="../TRC_t9501.htm"> ALLAY, 2009 </a> <br> </td> <td> aliskiren 300 mg<br>  <i>versus</i> <br> losartan 100 mg </td> <td> patients with hypertension, increased ventricular wall thickness, and body mass index >25 kg/m2 </td> <td> follow-up 9 months<br> n=154/152<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="../TRC_t9502.htm"> Andersen, 2008 </a> <br> </td> <td> aliskiren 150 mg (up to 300mg) daily<br>  <i>versus</i> <br> ramipril 5 mg (up to 10mg) daily </td> <td> </td> <td> follow-up 26 weeks<br> n=-9/-9<br> Parallel groups<br> double blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>Schmieder (vs HCTZ), 2009 : </b> Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen HLong-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. <i>Circulation 2009;119:417-25</i> [PMID 19139391] </p> <p> <b>AVOID, 2008 : </b> Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NKAliskiren combined with losartan in type 2 diabetes and nephropathy. <i>N Engl J Med 2008;358:2433-46</i> [PMID 18525041] </p> <p> <b>ALLAY, 2009 : </b> Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf BEffect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. <i>Circulation 2009;119:530-7</i> [PMID 19153265] </p> <p> <b>Andersen, 2008 : </b> Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DLComparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. <i>J Hypertens 2008;26:589-99</i> [PMID 18300872] </p>